CD274 and urothelial carcinoma: For example, in triple-negative breast cancer and urothelial carcinoma, approval for atezolizumab monotherapy or combined therapy is given in concern of PD-L1 expression evaluated on immune cells only as percent of tumour area occupied by immune cells [29,30].